24/7 Market News Snapshot 01 April, 2025 – ZYNEX INC (NASDAQ:ZYXI)
DENVER, Colo., 01 April, 2025 (247marketnews.com) – (NASDAQ:ZYXI) are discussed in this article.
Zynex Inc. (ZYXI) is experiencing a notable resurgence in its stock performance, with shares opening at $2.18 and exhibiting a substantial increase of 11.32% to a current trading price of $2.449. The trading volume has surged to 689.27K shares, reflecting strong investor interest and potential confidence in the company’s market trajectory. Analysts are observing key resistance levels around $2.50, while support is noted near the opening price, suggesting a positive technical outlook for the stock in the near term.
However, amid this positive momentum, Zynex faces significant legal challenges, as a securities class action lawsuit has been initiated against the company in the United States District Court for the District of Colorado. The lawsuit alleges that Zynex and specific current and former executives engaged in deceptive practices, resulting in misleading financial disclosures between March 13, 2023, and March 11, 2025. The claims are based on assertions of inflated product shipments and fraudulent insurance claims that have undermined Zynex’s revenue integrity.
The legal situation escalated following a concerning report published by a medical journal, which accused Zynex of participating in an “oversupplying scheme.” Additionally, Zynex’s recent financial reports indicated a significant revenue shortfall due to delayed payments from crucial partners, including the Tricare program, which is currently reviewing past claims. Shareholders who purchased Zynex securities during the stated period are urged to evaluate their eligibility for recovery as the deadline to file a motion for lead plaintiff status is set for May 19, 2025. This dual narrative of stock performance and impending legal scrutiny underscores a complex chapter for Zynex, highlighting the critical need for corporate transparency in the medical device sector.